Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide.
Excellent balance sheet with proven track record.
Share Price & News
How has Pro-Dex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PDEX has not had significant price volatility in the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: PDEX exceeded the US Medical Equipment industry which returned 17% over the past year.
Return vs Market: PDEX exceeded the US Market which returned 16.2% over the past year.
Price Volatility Vs. Market
How volatile is Pro-Dex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StIs Pro-Dex, Inc.’s (NASDAQ:PDEX) 19% ROCE Any Good?
1 year ago | Simply Wall StIs Pro-Dex Inc's (NASDAQ:PDEX) 9.4% Better Than Average?
1 year ago | Simply Wall StPro-Dex Inc (NASDAQ:PDEX): Why Return On Capital Employed Is Important
Is Pro-Dex undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PDEX ($20.6) is trading above our estimate of fair value ($4.32)
Significantly Below Fair Value: PDEX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PDEX is good value based on its PE Ratio (18.4x) compared to the US Medical Equipment industry average (53.5x).
PE vs Market: PDEX is poor value based on its PE Ratio (18.4x) compared to the US market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: PDEX is poor value based on its PEG Ratio (2.9x)
Price to Book Ratio
PB vs Industry: PDEX is overvalued based on its PB Ratio (4.6x) compared to the US Medical Equipment industry average (4.1x).
How is Pro-Dex forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PDEX's forecast earnings growth (6.4% per year) is above the savings rate (2.2%).
Earnings vs Market: PDEX's earnings (6.4% per year) are forecast to grow slower than the US market (22.6% per year).
High Growth Earnings: PDEX's earnings are forecast to grow, but not significantly.
Revenue vs Market: PDEX's revenue (2.8% per year) is forecast to grow slower than the US market (9.4% per year).
High Growth Revenue: PDEX's revenue (2.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PDEX's Return on Equity is forecast to be high in 3 years time
How has Pro-Dex performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PDEX has a high level of non-cash earnings.
Growing Profit Margin: PDEX's current net profit margins (14.5%) are higher than last year (13%).
Past Earnings Growth Analysis
Earnings Trend: PDEX has become profitable over the past 5 years, growing earnings by 32.2% per year.
Accelerating Growth: PDEX's earnings growth over the past year (29.7%) is below its 5-year average (32.2% per year).
Earnings vs Industry: PDEX earnings growth over the past year (29.7%) exceeded the Medical Equipment industry 1.2%.
Return on Equity
High ROE: PDEX's Return on Equity (26%) is considered high.
How is Pro-Dex's financial position?
Financial Position Analysis
Short Term Liabilities: PDEX's short term assets ($20.6M) exceed its short term liabilities ($4.4M).
Long Term Liabilities: PDEX's short term assets ($20.6M) exceed its long term liabilities ($6.6M).
Debt to Equity History and Analysis
Debt Level: PDEX's debt to equity ratio (23.8%) is considered satisfactory.
Reducing Debt: PDEX's debt to equity ratio has increased from 1.1% to 23.8% over the past 5 years.
Debt Coverage: PDEX's debt is well covered by operating cash flow (62.1%).
Interest Coverage: PDEX's interest payments on its debt are well covered by EBIT (38.1x coverage).
What is Pro-Dex current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PDEX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PDEX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PDEX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PDEX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PDEX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Rick Van Kirk (59 yo)
Mr. Richard Lee Van Kirk, Jr., also known as Rick, has been the Chief Executive Officer and President of Pro-Dex Inc., since January 12, 2015 and has been its Chief Operating Officer since April 23, 2013. ...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD454.76K) is about average for companies of similar size in the US market ($USD606.98K).
Compensation vs Earnings: Rick's compensation has increased by more than 20% in the past year.
|CEO, President||5.58yrs||US$454.76k||1.03% |
|Independent Director||7.58yrs||US$18.00k||no data|
|Independent Director||7.58yrs||US$25.00k||0.021% |
|Independent Chairman of the Board||no data||US$18.00k||2.51% |
|Independent Director||7.58yrs||US$18.00k||0.16% |
|Director||0.67yr||no data||0.18% |
Experienced Board: PDEX's board of directors are considered experienced (7.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pro-Dex, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Pro-Dex, Inc.
- Ticker: PDEX
- Exchange: NasdaqCM
- Founded: 1978
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$78.814m
- Shares outstanding: 3.81m
- Website: https://www.pro-dex.com
Number of Employees
- Pro-Dex, Inc.
- 2361 McGaw Avenue
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PDEX||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Aug 1986|
|PDXN||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 1986|
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/05 23:36|
|End of Day Share Price||2020/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.